Submitted:
11 September 2024
Posted:
12 September 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. HPV Genotyping Test and LBC
2.3. Colposcopy and Punch Biopsy
2.4. Immunohistochemistry
2.5. Light Microscopy Techniques for Cell Imaging
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. Epub 2021 Feb 4. PMID: 33538338. [CrossRef]
- Fitzpatrick MB, Hahn Z, Mandishora RSD, et al. Whole-Genome Analysis of Cervical Human Papillomavirus Type 35 from rural Zimbabwean Women. Sci Rep. 2020;10(1). [CrossRef]
- de Sanjosé S, Alemany L, Castellsagué X, Bosch FX. Human papillomavirus vaccines and vaccine implementation. Women’s Health. 2008;4(6). [CrossRef]
- Chen Z, Schiffman M, Herrero R, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One. 2011;6(5). [CrossRef]
- Cohen C, Lawson D, Jiang J, Siddiqui MT. Automated in situ hybridization for human papilloma virus. Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):619-22. PMID: 24897064. [CrossRef]
- Lodde M, Mian C, Mayr R, Comploj E, Trenti E, Melotti R, Campodonico F, Maffezzini M, Fritsche HM, Pycha A. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading. Int J Urol. 2014 Oct;21(10):968-72. Epub 2014 Jun 19. PMID: 24947145. [CrossRef]
- Ishida M, Ohashi S, Kizaki Y, Naito J, Horiguchi K, Harigaya T. Expression profiling of mouse placental lactogen II and its correlative genes using a cDNA microarray analysis in the developmental mouse placenta. J Reprod Dev. 2007 Feb;53(1):69-76. Epub 2006 Oct 24. PMID: 17062983. [CrossRef]
- Guo M, Gong Y, Deavers M, Silva EG, Jan YJ, Cogdell DE, Luthra R, Lin E, Lai HC, Zhang W, Sneige N. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008 Jan;46(1):274-80. Epub 2007 Oct 31. PMID: 17977987; PMCID: PMC2224284. [CrossRef]
- Chalcarz, M.; Z˙ urawski, J. Injection of Aquafilling® for Breast Augmentation Causes Inflammatory Responses Independent of Visible Symptoms. Aesthet. Plast. Surg. 2021, 45, 481–490.
- Zito Marino F, Ronchi A, Stilo M, Cozzolino I, La Mantia E, Colacurci N, Colella G, Franco R. Multiplex HPV RNA in situ hybridization/p16 immunohistochemistry: a novel approach to detect papillomavirus in HPV-related cancers. A novel multiplex ISH/IHC assay to detect HPV. Infect Agent Cancer. 2020 Jul 14;15:46. PMID: 32684947; PMCID: PMC7362547. [CrossRef]
- Sheng Z, Minato H, Sasagawa T, et al. Detection of high-risk human papillomavirus subtypes in cervical glandular neoplasia by in situ hybridization. Int J Clin Exp Pathol. 2013;6(10).
- Tase T, Okagaki T, Clark BA, et al. Human Papillomavirus Types and Localization in Adenocarcinoma and Adenosquamous Carcinoma of the Uterine Cervix: A study by in Situ DNA Hybridization. Cancer Res. 1988;48(4).
- Milde-Langosch K, Riethdorf S, Kraus-Pöppinghaus A, Riethdorf L, Löning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Archiv. 2001;439(1). [CrossRef]
- Samama B, Plas-Roser S, Schaeffer C, Chateau D, Fabre M, Boehm N. HPV DNA detection by in situ hybridization with catalyzed signal amplification on thin-layer cervical smears. Journal of Histochemistry and Cytochemistry. 2002;50(10). [CrossRef]
- Pruski D, Millert-Kalinska S, Lewek A, Kedzia W. Sensitivity and specificity of HR HPV E6/E7 mRNA test in detecting cervical squamous intraepithelial lesion and cervical cancer. Ginekol Pol. 2019;90(2):66-71. PMID: 30860271. [CrossRef]
- Zappacosta R, Colasante A, Viola P, D’Antuono T, Lattanzio G, Capanna S, Gatta DM, Rosini S. Chromogenic in situ hybridization and p16/Ki67 dual staining on formalin-fixed paraffin-embedded cervical specimens: correlation with HPV-DNA test, E6/E7 mRNA test, and potential clinical applications. Biomed Res Int. 2013;2013:453606. Epub 2013 Nov 24. PMID: 24369532; PMCID: PMC3858005. [CrossRef]
- Hui C, Bai H, Liu J, Lu X, Wang S, Zhang Z, Jin M, Wang Y, Liu Y. Accuracy of HPV E6/E7 mRNA examination using in situ hybridization in diagnosing cervical intraepithelial lesions. Diagn Pathol. 2021 Feb 19;16(1):13. PMID: 33608003; PMCID: PMC7896359. [CrossRef]
- Pruski, D.; Millert-Kalińska, S.; Łagiedo, M.; Sikora, J.; Jach, R.; Przybylski, M. Effect of HPV Vaccination on Virus Disappearance in Cervical Samples of a Cohort of HPV-Positive Polish Patients. J. Clin. Med. 2023, 12, 7592. [CrossRef]
- Takamoto D, Kawahara T, Kasuga J, Sasaki T, Yao M, Yumura Y, Uemura H. The analysis of human papillomavirus DNA in penile cancer tissue by in situ hybridization. Oncol Lett. 2018 May;15(5):8102-8106. Epub 2018 Mar 26. PMID: 29731917; PMCID: PMC5920620. [CrossRef]






| Characteristics | Values |
| N | 72 |
| Age, years, Me (Q1; Q3) | 33.00 (28.75;37.00) |
| Histopathological diagnosis, n (%) | |
| CIN1 | 28 (38.9) |
| CIN2 | 22 (30.6) |
| CIN3 | 20 (27.8) |
| No pathology | 2 (2.8) |
| ISH II, Me (Q1; Q3) | 58.45 (33.36;87.99) |
| ISH III, Me (Q1; Q3) | 375.60 (134.90;2400.16) |
| LBC result, n (%) | |
| NILM | 3 (4.2) |
| AS-CUS | 11 (15.3) |
| LSIL | 32 (44.4) |
| ASC-H | 15 (20.8) |
| HSIL | 11 (15.3) |
| HPV, n (%) | |
| Positive | 64 (88.9) |
| Negative | 8 (11.1) |
| HPV genotype, n (%)* | |
| 6 or 11 | 8 (11.1) |
| Any of 16, 18, 31, 33, 35, 45, 52, 56, 58, 66 | 53 (73.6) |
| Other positive | 22 (30.6) |
| Variables | ISH II level | MD (95% CI) | p |
| LBC result | |||
| NILM | 79.12 (52.51;177.78) | - | - |
| AS-CUS | 63.55 (44.55;79.13) | - | 0.786 |
| LSIL | 61.15 (35.89;92.27) | ||
| ASC-H | 50.77 (32.00;102.45) | ||
| HSIL | 46.81 (29.84;69.30) | ||
| HPV | |||
| yes | 52.28 (33.12;85.47) | -28.24 (-88.01;3.05) | 0.072 |
| no | 80.52 (67.09;163.84) | ||
| HPV genotypes | |||
| 6 or 11 | |||
| yes | 48.76 (42.74;54.36) | -14.66 (-34.26;17.44) | 0.809 |
| no | 63.42 (32.46;92.27) | ||
| Any of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66 | |||
| yes | 57.15 (31.72;86.34) | -8.67 (-41.39;7.72) | 0.188 |
| no | 65.82 (47.26;115.24) | ||
| Histopathological diagnosis | |||
| CIN1 | 63.42 (36.07;85.47) | 11.14 (-16.15; -26.32) | 0.527 |
| CIN2 + CIN3 | 52.28 (35.59;71.45) |
| Variables | ISH III level | MD (95% CI) | p |
| LBC result | |||
| NILM | 198.92 (127.20;220.16) | - | - |
| AS-CUS | 166.58 (147.58;2379.48) | - | 0.828 |
| LSIL | 334.40 (122.33;2045.52) | ||
| ASC-H | 396.79 (215.43;3932.40) | ||
| HSIL | 1031.62 (135.07;6098.14) | ||
| HPV | |||
| positive | 318.25 (117.75;1954.46) | -7961.82 (-17230.00;-199.21) |
0.005 |
| negative | 8280.07 (1805.37;20100.63) | ||
| HPV genotypes | |||
| 6 or 11 | |||
| yes | 110.96 (85.23;195.17) | -317.05 (-1972.19;-13.71) | 0.037 |
| no | 428.01 (153.80;2828.15) | ||
| Any of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66 | |||
| yes | 346.67 (140.08;1997.89) | -1660.38 (-4089.04;65.29) |
0.157 |
| no | 2007.05 (141.99;12071.24) | ||
| Histopathological diagnosis | |||
| CIN1 | 375.60 (137.87;3007.58) | -338.61 (-929.97;516.39) |
0.812 |
| CIN2 + CIN3 | 714.21 (99.78;2757.10) |
| Variables | HPV | Kappa coefficient | p | |
| yes (n = 64) | no (n = 8) | |||
| CIN1 | ||||
| yes | 22 (34.4) | 6 (75.0) | -0.14 | 0.917 |
| No | 42 (65.6) | 2 (25.0) | ||
| CIN2 | ||||
| yes | 20 (31.2) | 2 (25.0) | 0.02 | 0.413 |
| No | 44 (68.8) | 6 (75.0) | ||
| CIN3 | ||||
| yes | 20 (31.2) | 0 (0.0) | 0.09 | 0.132 |
| No | 44 (68.8) | 8 (100.0) | ||
| Variable | CIN2 + CIN3 | Sensitivity, % | Specificity, % | PPV, % | NPV, % | Accuracy, % | |||
| Yes, n = 42 |
No, n = 30 |
Total, n = 72 |
|||||||
| ASC-US | + | 4 | 7 | 11 | 9.52 (2.66-22.62) | 76.67 (57.72-90.07) | 36.36 (15.51-64.01) | 37.70 (32.68-43.01) | 37.50 (26.32-48.68) |
| - | 38 | 23 | 61 | ||||||
| LSIL | + | 16 | 16 | 32 | 38.10 (23.57-54.36) | 46.67 (28.34-65.67) | 50.00 (37.51-62.49) | 35.00 (25.56-45.79) | 41.67 (30.28-53.05) |
| - | 26 | 14 | 40 | ||||||
| ASC-H | + | 11 | 4 | 15 | 26.19 (13.86-42.04) | 86.67 (69.28-96.24) | 73.33 (49.19-88.65) | 45.61 (40.03-51.31) | 51.39 (39.84-62.93) |
| - | 31 | 26 | 57 | ||||||
| HSIL | + | 10 | 1 | 11 | 23.81 (12.05-39.45) | 96.67 (82.78-99.92) | 90.91 (57.47-98.67) | 47.54 (43.04-52.08) | 54.17 (42.66-65.68) |
| - | 32 | 29 | 61 | ||||||
| ISH II | + | 42 | 30 | 72 | 100.00 (91.59-100.00) | 0.00 (0.00-11.57) | 58.33 (56.21-61.17) | - | 58.33 (46.95-69.72) |
| - | 0 | 0 | 0 | ||||||
| ISH III | + | 42 | 30 | 72 | 100.00 (91.59-100.00) | 0.00 (0.00-11.57) | 58.33 (56.21-61.17) | - | 58.33 (46.95-69.72) |
| - | 0 | 0 | 0 | ||||||
| HPV | + | 40 | 24 | 64 | 95.24 (83.84-99.42) | 20.00 (7.71-38.57) | 62.50 (57.92-66.87) | 75.00 (39.38-93.27) | 63.89 (52.79-74.98) |
| - | 2 | 6 | 8 | ||||||
| HPV 6 or 11 | + | 4 | 4 | 8 | 9.52 (2.66-22.62) | 86.67 (69.28-96.24) | 50.00 (21.34-78.66) | 40.62 (36.57-44.81) | 41.67 (30.28-53.05) |
| - | 38 | 26 | 64 | ||||||
| HPV group 2* | + | 35 | 18 | 53 | 83.33 (68.64-93.03) | 40.00 (22.66-59.40) | 66.04 (58.49-72.85) | 63.16 (43.37-79.33) | 65.28 (54.28-76.27) |
| - | 7 | 12 | 19 | ||||||
| Variable | HPV 6 or 11 | Sensitivity, % | Specificity, % | PPV, % | NPV, % | Accuracy, % | |||
| Yes, n = 8 |
No, n = 64 |
Total, n = 72 |
|||||||
| ISH II | + | 8 | 64 | 72 | 100.00 (63.06-100.00) | 0.00 (0.00-5.60) | 11.11 (7.72-12.20) | - | 11.11 (3.85-18.37) |
| - | 0 | 0 | 0 | ||||||
| Variable | HPV 16, 18, 31, 33, 35, 45, 52, 56, 58, 66 | Sensitivity, % | Specificity, % | PPV, % | NPV, % | Accuracy, % | |||
| Yes, n = 53 | No, n = 19 | Total, n = 72 | |||||||
| ISH III | + | 53 | 19 | 72 | 100.00 (93.28-100.00) | 0.00 (0.00-17.65) | 73.61 (72.03-77.08) | - | 73.61 (63.43-83.79) |
| - | 0 | 0 | 0 | ||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).